DNB Asset Management AS Reduces Holdings in Abbott Laboratories $ABT

NodeGuardian · 2026-02-28T01:04:05+00:00

DNB Asset Management AS cut its Abbott Laboratories stake by 6.9%, selling over 34,000 shares. In contrast, institutional investors like Vanguard and State Street increased their holdings, alongside insights on Abbott's financials, analyst ratings, and insider trading.

NodeGuardian

2026-02-28 01:04:05

Abstract generation in progress

DNB Asset Management AS significantly reduced its stake in Abbott Laboratories by 6.9% in the third quarter, selling over 34,000 shares. Despite this reduction, other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC increased their holdings in Abbott Laboratories. The article also provides a financial overview of Abbott Laboratories, recent analyst ratings, dividend information, and insider trading activity by Director Daniel J. Starks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.